Core Viewpoint - Qingdao Sanbai Shuo Health Technology Co., Ltd. is set to release 177,556,827 shares for trading on October 20, 2025, which represents 72.8361% of the company's total share capital [2][21][22]. Group 1: Share Release Details - The number of shares to be released for trading is 177,556,827, accounting for 72.8361% of the total share capital [2][22]. - The total share capital of the company is 243,775,914 shares, with 182,831,935 shares subject to restrictions and 60,943,979 shares freely tradable [4][5]. - The release of shares follows the approval from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [4]. Group 2: Shareholder Commitments - Three shareholders are involved in the release of restricted shares: Qingdao Haishuo Health Industry Development Co., Ltd., J.LU INVESTMENTS LLC, and Ningbo Hechuang Caizhi Investment Partnership [6][23]. - Shareholders have committed to a lock-up period of 36 months from the listing date, during which they will not transfer or manage their shares [6][9]. - If the stock price falls below the initial public offering price for 20 consecutive trading days within the first six months, the lock-up period will be extended by an additional six months [8][9][12]. Group 3: Compliance and Oversight - The company has confirmed that all shareholders have adhered to their commitments regarding the lock-up period and have not engaged in any non-operational use of company funds [20]. - The underwriter, CITIC Securities Co., Ltd., has verified that the release of restricted shares complies with relevant regulations and shareholder commitments [26]. - The company will continue to follow regulations regarding shareholding changes for directors and senior management after the release of shares [25].

（编辑 楚丽君） 证券日报网讯 10月15日晚间，三柏硕发布公告称，公司本次解除限售股份为首次公开发行前已发行的 股份。本次解除限售股份数量为177，556，827股，占公司总股本的72.8361%。本次解除限售股份的上 市流通日：2025年10月20日（星期一）。 ...

Group 1 - Company Sanbai Shuo announced that approximately 178 million restricted shares will be unlocked and listed for circulation on October 20, 2025, accounting for about 72.84% of the company's total share capital [1] - The annualized interest rate for renting silver has surged to 35%, indicating a significant opportunity in the silver market [1] - There is a global trend of silver being airlifted to the UK for profit, suggesting a major market movement and potential investment opportunities [1]

证券代码：001300 证券简称：三柏硕 公告编号：2025-047 青岛三柏硕健康科技股份有限公司 首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.青岛三柏硕健康科技股份有限公司（以下简称"公司"、"本公司"、"三柏 硕"）本次解除限售股份为首次公开发行前已发行的股份。本次解除限售股份数 量为 177,556,827 股，占公司总股本的 72.8361%。 2.本次解除限售股份的上市流通日：2025 年 10 月 20 日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于核准青岛三柏硕健康科技股份有限公司首 次公开发行股票的批复》（证监许可〔2022〕2054 号）核准，并经深圳证券交易 所《关于青岛三柏硕健康科技股份有限公司人民币普通股股票上市的通知》（深 证上〔2022〕997 号）同意，公司首次公开发行人民币普通股股票 60,943,979 股， 于 2022 年 10 月 19 日在深圳证券交易所主板上市。 首次公开发行前，公司总股本为 182,831,935 ...

关于青岛三柏硕健康科技股份有限公司首次公开发行前 中信建投证券股份有限公司 已发行股份解除限售上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为青岛三柏硕健康科技股份有限公司（以下简称"三柏硕"或"公司"）首次 公开发行股票并上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对三柏硕首次公开发行前已发行股份解除限 售并上市流通事项进行了核查，具体情况如下： 一、首次公开发行前已发行股份概况 2、本公司在发行人上市前直接或间接持有的发行人股份在上述锁定期满后 两年内减持的，减持价格（如因派发现金红利、送股、转增股本、增发新股等原 因进行除权、除息的，须按照中国证监会、深圳证券交易所的有关规定作相应调 整）不低于首次公开发行价格。 3、三柏硕股票上市后 6 个月内，如三柏硕股票连续 20 个交易日的收盘价（如 因派发现金红利、送股、转增股本、增发新股等原因进行除权、除息的，须按照 中 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-048 青岛三柏硕健康科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日 分别召开了第二届董事会第八次会议、第二届监事会第八次会议，审议通过了《关 于使用部分暂时闲置募集资金进行现金管理的议案》，同意在确保不影响募集资 金投资计划正常进行和募集资金安全的情况下，公司使用最高不超过人民币5亿 元的暂时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月 内，单个投资产品的投资期限不超过12个月。额度范围内资金可循环滚动使用。 具体内容详见公司于2025年4月28日披露的《关于使用部分暂时闲置募集资金进 行现金管理的公告》（公告编号：2025-025）。 根据上述决议，公司近期使用闲置募集资金（含现金管理收益和募集资金利息） 购买了部分理财产品，具体事项公告如下： 序 号 申购 主体 交易 对方 产品 名称 产品 类型 金额 （元） 预期年 化收益 起始 ...

Core Viewpoint - Qingdao Sanbai Shuo Health Technology Co., Ltd. has announced its plan to apply for a comprehensive credit limit of up to RMB 800 million from banks and financial institutions for the year 2025, along with related guarantee matters [1] Group 1: Credit Limit and Guarantee Overview - The company plans to apply for a comprehensive credit limit not exceeding RMB 800 million for 2025, which will be used for financing through collateral and guarantees provided by its wholly-owned subsidiaries [1] - The credit limit and guarantee will be valid from the date of approval at the 2024 annual shareholders' meeting until the 2025 annual shareholders' meeting [1] Group 2: Progress of Credit Limit and Guarantee - The company has applied for a comprehensive credit limit of RMB 40 million from China Minsheng Bank Qingdao Branch, with guarantees provided by its wholly-owned subsidiary and the actual controller [2] - The guarantees are irrevocable joint liability guarantees, and no fees will be charged to the company for these guarantees [2] Group 3: Basic Information of the Guaranteed Party - The recent financial indicators of Qingdao Sanbai Shuo Health Technology Co., Ltd. have been audited by a certified public accountant [3] Group 4: Main Content of Guarantee Agreement - The guarantee period is three years from the expiration of the debt performance period, covering principal, interest, penalties, and other related costs [5] Group 5: Board of Directors' Opinion - The board of directors has approved the credit and guarantee matters, confirming they align with the company's actual needs and do not harm the interests of the company and its shareholders [6] Group 6: Cumulative External Guarantee Amount - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 461 million, representing 43.67% of the latest audited net assets [7]

Core Viewpoint - Qingdao Sanbaisuo Health Technology Co., Ltd. announced progress on credit and guarantee, planning to apply for a comprehensive credit limit of up to 800 million yuan by 2025 [1] Group 1: Credit Application - The company and its subsidiaries intend to apply for a comprehensive credit limit of no more than 800 million yuan from financial institutions, with the validity period until the annual general meeting in 2025 [1] - The company has applied for a comprehensive credit limit of 40 million yuan from Minsheng Bank Qingdao Branch, guaranteed by its wholly-owned subsidiary Haishuo Fitness and actual controller Zhu Xilong, without any fees or counter-guarantees [1] Group 2: Guarantee and Financial Status - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is 46.1 million yuan, accounting for 43.67% of the most recent audited net assets [1] - All guarantees are within the consolidated financial statements, with no overdue or abnormal situations reported [1]

证券代码：001300 证券简称：三柏硕 公告编号：2025-046 青岛三柏硕健康科技股份有限公司 关于公司向银行申请授信额度及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、授信额度及担保情况概述 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日 分别召开第二届董事会第八次会议、第二届监事会第八次会议，于2025年5月20 日召开2024年年度股东大会，审议通过了《关于2025年度向银行等金融机构申 请授信额度及担保事项的议案》，同意2025年度公司及全资子公司拟向银行等 金融机构申请额度不超过人民币8亿元的综合授信。在上述授信总额额度内，公 司将根据实际需要由公司及全资子公司以其拥有的资产为其自身融资提供抵押、 质押担保；由公司与全资子公司之间或全资子公司之间以信用或资产抵押、质 押方式相互提供担保和反担保，包括对资产负债率70%以上的全资子公司进行 担保；接受由公司控股股东青岛海硕健康产业发展有限公司、实际控制人朱希 龙先生以信用或资产抵押、质押方式提供担保（公司不提供反担保且免于支付 担保费用）以及法律 ...

Core Insights - A new company named Baixing Zhishu (Shanghai) Information Technology Co., Ltd. has been established, focusing on various aspects of artificial intelligence and IoT technology [1] Company Overview - The company is involved in the development of artificial intelligence application software, foundational software, and theoretical algorithms [1] - It also engages in research and development of IoT technology and provides remote health management services [1] Ownership Structure - Baixing Zhishu is co-owned by Sanbai Shuo (stock code: 001300) among other stakeholders [1]